ADVB (Advanced Biomed) Return-on-Tangible-Asset: -18.20% (As of Mar. 2026)


ADVB Advanced Biomed Inc ADVB
12 GF Score
Price $5.07
! 1 Warning Sign
View Full Analysis

What is Advanced Biomed Return-on-Tangible-Asset?

Advanced Biomed ADVB +3.10% 12 Return-on-Tangible-Asset is -18.20% as of Mar. 2026. GuruFocus rates ADVB with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 214 Medical Diagnostics & Research companies, Advanced Biomed ranks better than 98.13% on this metric.

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Advanced Biomed's annualized Net Income for the quarter that ended in Mar. 2026 was $-1.96 Mil. Advanced Biomed's average total tangible assets for the quarter that ended in Mar. 2026 was $10.75 Mil. Therefore, Advanced Biomed's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -18.20%.

The historical rank and industry rank for Advanced Biomed's Return-on-Tangible-Asset or its related term are showing as below:

ADVB' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -182.6   Med: -70.09   Max: 62.09
Current: 62.09

During the past 5 years, Advanced Biomed's highest Return-on-Tangible-Asset was 62.09%. The lowest was -182.60%. And the median was -70.09%.

ADVB's Return-on-Tangible-Asset is ranked better than
98.13% of 214 companies
in the Medical Diagnostics & Research industry
Industry Median: -2.52 vs ADVB: 62.09

Advanced Biomed  (NAS:ADVB) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Advanced Biomed Return-on-Tangible-Asset Related Terms


Advanced Biomed Return-on-Tangible-Asset Historical Data

* Premium members only.

The historical data trend for Advanced Biomed's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advanced Biomed Return-on-Tangible-Asset Chart

Advanced Biomed Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Return-on-Tangible-Asset
-182.60 -110.24 -70.09 -64.02 -60.06

Advanced Biomed Quarterly Data
Jun21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -87.04 -38.00 -24.27 320.95 -18.20

ADVB vs MBAI, XWEL, NDRA: Return-on-Tangible-Asset Comparison

For the Diagnostics & Research subindustry, Advanced Biomed's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advanced Biomed Return-on-Tangible-Asset vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Advanced Biomed's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Advanced Biomed's Return-on-Tangible-Asset falls into.


ADVB
12GF Score
Advanced Biomed Inc ADVB
Return-on-Tangible-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Advanced Biomed Return-on-Tangible-Asset Calculation

Advanced Biomed's annualized Return-on-Tangible-Asset for the fiscal year that ended in Jun. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=-3.259/( (4.341+6.512)/ 2 )
=-3.259/5.4265
=-60.06 %

Advanced Biomed's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-1.956/( (10.851+10.646)/ 2 )
=-1.956/10.7485
=-18.20 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2026) net income data.

What does a Return-on-Tangible-Asset of -18.20% mean?
Advanced Biomed (ADVB) has a Return-on-Tangible-Asset of -18.20% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Advanced Biomed and its competitors. According to the industry distribution chart, Advanced Biomed ranks #4 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 1.9%.
Is Advanced Biomed's Return-on-Tangible-Asset too high?
Advanced Biomed's current Return-on-Tangible-Asset is -18.20%. Based on the distribution chart, Advanced Biomed ranks #4 out of 214 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Advanced Biomed has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Advanced Biomed's Return-on-Tangible-Asset compare to MBAI and XWEL?
According to the Medical Diagnostics & Research industry distribution chart, Advanced Biomed ranks #4 out of 214 companies for Return-on-Tangible-Asset. This places Advanced Biomed in the top 2% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Asset depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Advanced Biomed and its competitors. Advanced Biomed's current Return-on-Tangible-Asset is -18.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Biomed stock overvalued right now?
Advanced Biomed (ADVB) has a current Return-on-Tangible-Asset of -18.20%. The current Return-on-Tangible-Asset is -18.20%. Advanced Biomed's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Advanced Biomed (ADVB), the current Return-on-Tangible-Asset is -18.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Advanced Biomed Business Description

Address No. 689-85 Xiaodong Road, Yongkang District, Tainan, TWN
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.
12GF Score

Get the complete analysis for ADVB

Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.07
Price